<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988984</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1745</org_study_id>
    <nct_id>NCT04988984</nct_id>
  </id_info>
  <brief_title>Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)</brief_title>
  <acronym>New Assay TB</acronym>
  <official_title>Development of Device Kit for Rapid and Sensitive Diagnostic Method for the Tuberculosis; Using Amine Groups Called HI(Homobifunctional Imidoesters),Negative Charge of the Pathogen and Formed Electrical Bonding to Isolate and Concentrate the Pathogen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is intended for patients who have been admitted to the outpatient or emergency room or are&#xD;
      hospitalized For patients who diagnose pulmonary tuberculosis or extrapulmonary tuberculosis&#xD;
      using Xpert TB/RIF, additionally, diagnose pulmonary tuberculosis or extrapulmonary&#xD;
      tuberculosis using a new diagnostic method, and check the test results. Check whether the&#xD;
      tuberculosis bacteria were actually cultured in the sample in the future, and compare the&#xD;
      sensitivity and specificity in each test.&#xD;
&#xD;
      Validation in animal model In an animal model (rat) with chronic obstructive pulmonary&#xD;
      disease that shows similar characteristics to tuberculosis destructive lung, It will be&#xD;
      investigated whether the HI method can be validated by separating and concentrating&#xD;
      microbiome for various pathogens including Mycobacterium tuberculosis using HI method.&#xD;
      Confirm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Usefulness of Pulmonary Tuberculosis Diagnosis A comparison of the new diagnostic method with&#xD;
      the Xpert TB/RIF test, which is widely used in clinical practice, that can quickly diagnose&#xD;
      pulmonary tuberculosis within 1-2 days. ; Considering the sensitivity of the Xpert TB/RIF&#xD;
      test as 70% and the sensitivity of the new diagnostic method as 90%, the number of patients&#xD;
      with pulmonary tuberculosis required to confirm that the new diagnostic method is useful is&#xD;
      estimated as 90 (study power 90%, alpha error = 0.05). And, if 200 patients with suspected&#xD;
      pulmonary tuberculosis are registered, it is possible to verify the clinical usefulness&#xD;
      compared to Xpert TB/RIF even in 60 AFB smear negative patients. In addition, for the same&#xD;
      reason, if 150 additional patients who underwent bronchoscopy were enrolled, it would be&#xD;
      possible to compare the diagnosis rate and utility of sputum and bronchoscopy fluid. Waiting&#xD;
      for the tuberculosis bacteria culture test for 6 weeks and using the final culture-positive&#xD;
      patient as a gold standard for tuberculosis diagnosis -Usefulness of extrapulmonary&#xD;
      tuberculosis diagnosis&#xD;
&#xD;
      Millet tuberculosis is disseminated tuberculosis through blood, and there are numerous&#xD;
      millet-like lesions in the lungs, but in fact, the positive rate of AFB smear is low due to&#xD;
      paucibacillary TB. It is planned to prove the usefulness of the new test method in 35 people&#xD;
      with millet tuberculosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 17, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Actual">November 17, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity when using Xpert TB/RIF tests with</measure>
    <time_frame>From date of experiment until the date of first documented progression assessed upto 100 months</time_frame>
    <description>Comparison of sensitivity and specificity of existing Xpert TB/RIF tests and new diagnostic methods using Homobifunctional Imidoesters (HI) compounds in diagnosing suspected cases of pulmonary tuberculosis and pulmonary tuberculosis&#xD;
And the sensitivity and specificity of these two test results are evaluated by waiting for the tuberculosis bacillus culture test for 6 weeks and using the final culture-positive patient as a gold standard for tuberculosis diagnosis.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Tuberculosis Infection</condition>
  <arm_group>
    <arm_group_label>Suspected TB</arm_group_label>
    <description>Patient suspected of TB undergoing diagnostic testing.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Oral swab,BAL, Pleural fluid,Sputum of agreed Subject&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        400&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pulmonary TB&#xD;
&#xD;
          -  Extrapulmonary TB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  under 19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Seiwon Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center, University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <state>Songpa</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Park YS, Hong SJ, Boo YK, Hwang ES, Kim HJ, Cho SH, Na KI, Cho EH, Shin SS. The national status of tuberculosis using nationwide medical records survey of patients with tuberculosis in Korea. Tuberc Respir Dis (Seoul). 2012 Jul;73(1):48-55. doi: 10.4046/trd.2012.73.1.48. Epub 2012 Jul 31.</citation>
    <PMID>23101024</PMID>
  </reference>
  <reference>
    <citation>Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1376-95. Review.</citation>
    <PMID>10764337</PMID>
  </reference>
  <reference>
    <citation>Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis (Seoul). 2015 Apr;78(2):47-55. doi: 10.4046/trd.2015.78.2.47. Epub 2015 Apr 2. Review.</citation>
    <PMID>25861336</PMID>
  </reference>
  <reference>
    <citation>Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, Caws M, Figaji A, Savic R, Solomons R, Thwaites GE; Tuberculous Meningitis International Research Consortium. Tuberculous meningitis. Nat Rev Neurol. 2017 Oct;13(10):581-598. doi: 10.1038/nrneurol.2017.120. Epub 2017 Sep 8. Review.</citation>
    <PMID>28884751</PMID>
  </reference>
  <reference>
    <citation>Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9;363(11):1005-15. doi: 10.1056/NEJMoa0907847. Epub 2010 Sep 1.</citation>
    <PMID>20825313</PMID>
  </reference>
  <reference>
    <citation>Rufai SB, Singh A, Singh J, Kumar P, Sankar MM, Singh S; TB Research Team. Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. J Infect. 2017 Aug;75(2):125-131. doi: 10.1016/j.jinf.2017.04.010. Epub 2017 May 10.</citation>
    <PMID>28501491</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 25, 2021</last_update_submitted>
  <last_update_submitted_qc>July 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sei Won Lee</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>New diagnostic platform,TB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

